CD33 and acute myeloid leukemia: However, a clinical trial aimed at treating R/R AML patients using single CAR T or double CAR T cells with CD33, CD38, CD56, CD123, CD117, CD133, CD34 or Muc1 was recently suspended as the therapeutic effect was not as expected (NCT03473457).